WO2000017334A3 - Analysis of ligand activated nuclear receptors i(in vivo) - Google Patents

Analysis of ligand activated nuclear receptors i(in vivo) Download PDF

Info

Publication number
WO2000017334A3
WO2000017334A3 PCT/IB1999/001682 IB9901682W WO0017334A3 WO 2000017334 A3 WO2000017334 A3 WO 2000017334A3 IB 9901682 W IB9901682 W IB 9901682W WO 0017334 A3 WO0017334 A3 WO 0017334A3
Authority
WO
WIPO (PCT)
Prior art keywords
nuclear receptors
vivo
analysis
ligands
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1999/001682
Other languages
French (fr)
Other versions
WO2000017334A9 (en
WO2000017334A2 (en
Inventor
Ludmila Solomin
De Urquiza Alexander Mata
Thomas Perlmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP99969436A priority Critical patent/EP1115853A2/en
Priority to AU59941/99A priority patent/AU5994199A/en
Publication of WO2000017334A2 publication Critical patent/WO2000017334A2/en
Publication of WO2000017334A3 publication Critical patent/WO2000017334A3/en
Anticipated expiration legal-status Critical
Publication of WO2000017334A9 publication Critical patent/WO2000017334A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to detection of ligands for nuclear receptors in vivo. In particular, the present invention provides transgenic constructs and transgenic animals, as well as assays using the same to detect ligands for nuclear receptors in transgenic animals. The transgenic constructs, transgenic animals and assays of the present invention are useful for identification and isolation of ligands for orphan receptors. In addition, the invention is useful for analyzing pharmacological properties of natural and synthetic ligands for nuclear receptors.
PCT/IB1999/001682 1998-09-23 1999-09-23 Analysis of ligand activated nuclear receptors i(in vivo) Ceased WO2000017334A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP99969436A EP1115853A2 (en) 1998-09-23 1999-09-23 Analysis of ligand activated nuclear receptors in vivo
AU59941/99A AU5994199A (en) 1998-09-23 1999-09-23 Analysis of ligand activated nuclear receptors (in vivo)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10148498P 1998-09-23 1998-09-23
US60/101,484 1998-09-23

Publications (3)

Publication Number Publication Date
WO2000017334A2 WO2000017334A2 (en) 2000-03-30
WO2000017334A3 true WO2000017334A3 (en) 2000-09-21
WO2000017334A9 WO2000017334A9 (en) 2001-07-05

Family

ID=22284894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/001682 Ceased WO2000017334A2 (en) 1998-09-23 1999-09-23 Analysis of ligand activated nuclear receptors i(in vivo)

Country Status (3)

Country Link
EP (1) EP1115853A2 (en)
AU (1) AU5994199A (en)
WO (1) WO2000017334A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548739B2 (en) * 1999-06-18 2003-04-15 City Of Hope Method for activating peroxisome proliferator activated receptor-γ
WO2002072874A1 (en) * 2001-03-14 2002-09-19 Fujisawa Pharmaceutical Co., Ltd. METHOD OF SCREENING HNF4α AGONIST
FI116851B (en) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Expression vector, its uses and process for its preparation and products containing it
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
AU2002367060A1 (en) 2001-12-21 2003-07-30 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
JPWO2004053124A1 (en) * 2002-12-06 2006-04-13 塩野義製薬株式会社 Screening method for therapeutic or preventive agent for diabetes
ATE496893T1 (en) 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc ISOQUINOLINONE DERIVATIVES AND THEIR USE AS MEDICATIONS
US20070271619A1 (en) * 2003-10-29 2007-11-22 Heinz Von Der Kammer Diagnostic and Therapeutic Use of the Human Dax-1 Gene and Protein for Neurodegenerative Diseases
US8703805B2 (en) 2005-06-27 2014-04-22 Exelixis Patent Company Llc Modulators of LXR
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
KR101676704B1 (en) 2009-05-28 2016-11-16 엑셀리시스 페이턴트 컴퍼니 엘엘씨 Lxr modulators
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
JP2015521602A (en) 2012-06-14 2015-07-30 アンブルックス, インコーポレイテッドAmbrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
JP6442475B2 (en) 2013-03-15 2018-12-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ LXR regulator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005292A1 (en) * 1997-07-22 1999-02-04 Chugai Seiyaku Kabushiki Kaisha Method for gene screening with the use of nuclear receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005292A1 (en) * 1997-07-22 1999-02-04 Chugai Seiyaku Kabushiki Kaisha Method for gene screening with the use of nuclear receptors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BALKAN W ET AL.: "Transgenic indicator mice for studying activated retinoic acid receptors during development", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 89, April 1992 (1992-04-01), WASHINGTON US, pages 3347 - 3351, XP002134850 *
LEMON B D ET AL: "Selective effects of ligands on vitamin D3 receptor- and retinoid receptor-mediated gene activation in vivo", MOLECULAR AND CELLULAR BIOLOGY, vol. 16, no. 3, March 1996 (1996-03-01), WASHINGTON US, pages 1006 - 1016, XP002134851 *
SOLOMIN L ET AL.: "Retinoid-X receptor signalling in the developing spinal cord", NATURE, vol. 395, 24 September 1998 (1998-09-24), LONDON GB, pages 398 - 402, XP002134853 *
WANG Y ET AL: "Ligand-inducible and liver-specific target gene expression in transgenic mice", NATURE BIOTECHNOLOGY., vol. 15, no. 3, March 1997 (1997-03-01), NATURE PUBLISHING, US, pages 239 - 243, XP002134852, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
EP1115853A2 (en) 2001-07-18
WO2000017334A9 (en) 2001-07-05
AU5994199A (en) 2000-04-10
WO2000017334A2 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
WO2000017334A3 (en) Analysis of ligand activated nuclear receptors i(in vivo)
Doucette et al. Development and preliminary validation of a microtiter plate-based receptor binding assay for paralytic shellfish poisoning toxins
DE69816474D1 (en) Stabilized particles of their preparation and use
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
GB2374415B (en) Human antibodies as detection reagents
EP1734368A3 (en) Annexins and autoantibodies used as markers for cancer
UA41476C2 (en) Appliance for high-sensitive magnetic detection of analyts (versions)
Costa et al. Comparative determination of paralytic shellfish toxins (PSTs) using five different toxin detection methods in shellfish species collected in the Aleutian Islands, Alaska
WO2004090154A3 (en) Acyl- phosphate and phosphonate probes and methods of their synthesis and use in proteomic analysis
WO2001016184A3 (en) Diagnostic assay for type 2 heparin-induced thrombocytopenia
ATE397215T1 (en) DISRUPTION OF IMMUNOASSAYS BY SUBSTANCES DERIVED FROM THE FRAMEWORK REGIONS OF ANTIBODIES
ATE226415T1 (en) LIVER FUNCTION TEST
DE50105263D1 (en) METHOD FOR THE ANALYSIS OF PROTEINS
WO2003043524A3 (en) Compositions and methods for accurate early pregnancy diagnosis
DE68921374D1 (en) Monoclonal antibody to human manganese superoxide dismutase, process for its preparation, test reagent, kit and test method using the same, process for diagnosing human ovarian cancer and heart attack.
EP1159614A4 (en) Diagnostic methods for asthma
CA2407760A1 (en) Methods for diagnosis of low grade astrocytoma
ATE184323T1 (en) NUCLEIC ACID DETECTION
WO2003093817A3 (en) Method of identifying ligands for nuclear receptors
GB0014054D0 (en) Allergen detection
WO2004078783A3 (en) Enzymes involved in apoptosis
AU4624200A (en) Identification of ligands for orphan receptors using mass spectrometry
CN208568797U (en) A kind of detection capsaicine time-resolved fluoroimmunoassay quantifies POCT kit
ATE184286T1 (en) HGPIIB FRAGMENTS AND THEIR USE IN IN VITRO METHODS FOR DETERMINING THROMBOTIC EVENTS OCCURRING IN VIVO
WO2000049948A3 (en) Urine collector

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 574235

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999969436

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 59941/99

Country of ref document: AU

AK Designated states

Kind code of ref document: C2

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGE 1/7, DRAWINGS, REPLACED BY A NEW PAGE 1/7; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZEDBY THE INTERNATIONAL SEARCHING AUTHORITY

WWP Wipo information: published in national office

Ref document number: 1999969436

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999969436

Country of ref document: EP